| Project/Area Number |
21590186
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | Mukogawa Women's University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
YAMAMORI Motohiro 武庫川女子大学, 薬学部, 講師 (10444613)
FUJITA Megumi 武庫川女子大学, 薬学部, 助手 (50509966)
|
|---|
| Project Period (FY) |
2009 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2011: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2010: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2009: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | 臨床薬学 / 腎臓がん / プロテオミクス / アポトーシス / 創薬ターゲット |
|---|
| Research Abstract |
The novel proteins, showing highly expressed in renal cell carcinoma were selected based on proteomics, and their functions were investigated in renal carcinoma cell lines. The results suggested they did not play a role in proliferate. Next, the effects of troglitazone, a PPARγ agonist, on renal carcinoma cell lines were examined, and it was revealed that the anti-tumor effects was independent of PPARγ and MAPK p38 pathway played an important role. In addition, 15-deoxy-Δ12, 14-prostaglandin J2 exhibited anti-tumor effects on renal carcinoma cell lines independently of the PPARγ pathway.
|
